<DOC>
	<DOCNO>NCT01479582</DOCNO>
	<brief_summary>Background : - Cord blood bank set collect store umbilical cord blood transplant . These transplant use treat different type cancer . In October 2011 , Food Drug Administration ( FDA ) begin consider cord blood biological drug . Most cord blood unit currently available cord blood bank United States country collect FDA set new standard . The unit meet standard set National Marrow Donor Program ( NMDP ) , collect , test , store exactly accord FDA standard . As result , new guideline state may use transplant transplant do part study . Researchers set study provide cord blood unit recipient study effect use . Objectives : - To provide access cord blood unit recipient whose best choice unit meet NMDP FDA standard . - To study effect cord blood transplant . Eligibility : - Individuals need cord blood transplant treat certain type cancer . Design : - Participants screen physical exam , medical history . They also blood test image study . - Participants cord blood transplant allow medical data collect study researcher .</brief_summary>
	<brief_title>Providing Access Cord Blood Units Transplants</brief_title>
	<detailed_description>Study Design : This study access distribution protocol unlicensed cryopreserved cord blood unit ( CBUs ) pediatric adult patient hematologic malignancy indication . Primary Objective : The primary aim study examine incidence neutrophil recovery ( Bullet ) 500/mm3 cord blood transplantation multi-institution set use CBUs Food Drug Administration ( FDA ) license . Secondary Objectives : In patient receive non-licensed CBU : - Assess incidence graft rejection - Assess incidence transmission infection - Assess incidence serious infusion reaction - Determine 1 year survival cord blood transplantation - Assess cumulative incidence acute graft vs. host disease ( GVHD ) grade II IV grade III IV - Assess cumulative incidence chronic GVHD - Determine platelet engraftment &gt; 20,000 mcL &gt; 50,000 mcL - Determine CBU-derived engraftment Eligibility Criteria : Inclusion Criteria - Patients FDA-specified indication ( see Appendix B detail ) : - Hematological malignancy - Certain lysosomal storage peroxisomal enzyme deficiency disorder - Hurler syndrome ( MPS I ) - Krabbe Disease ( Globoid Leukodystrophy ) - X-linked Adrenoleukodystrophy - Primary immunodeficiency diseases - Bone marrow failure - Beta-thalassemia - Signed informed consent ( sign assent , applicable ) - Pediatric adult patient age Exclusion Criteria - Patients receive license CBUs - Cord blood transplant recipients international transplant center Treatment Description : Treatment , include pre-transplant conditioning GVHD prophylaxis , occur per transplant center specification . Accrual Objective : In access distribution protocol , U.S. patient undergo transplant use unlicensed CBUs enrol accrual maximum . Accrual Period : The accrual period open end .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients FDAspecified indication : Hematological malignancy Certain lysosomal storage peroxisomal enzyme deficiency disorder Hurler syndrome ( MPS I ) Krabbe Disease ( Globoid Leukodystrophy ) Xlinked Adrenoleukodystrophy Primary immunodeficiency diseases Bone marrow failure Betathalassemia Signed inform consent ( sign assent , applicable ) Pediatric adult patient age EXCLUSION CRITERIA : Patients receive licensed CBUs Cord blood transplant recipients international transplant center</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 26, 2012</verification_date>
	<keyword>Adult Pediatric</keyword>
	<keyword>Unlicensed Cord Blood Unit IND</keyword>
	<keyword>NMDP</keyword>
	<keyword>Transplant</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>CML</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Myelodyplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Lysosomal Storage Diseases</keyword>
</DOC>